Beam Therapeutics to Present Initial BEAM-301 Trial Data
The company says initial Phase 1/2 data show restoration of endogenous glucose production after a single treatment, with dose-dependent improvements in key GSDIa endpoints.
BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIaInitial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa EndpointsSafety Profile of BEAM-301 Consistent with LNP-ba…